{{(R)-2-(BIS-CARBOXYMETHYL-AMINO)-3-[(4,4-DIPHENYL-CYCLOHEXYLOXY)-HYDROXY-PHOSPHORYLOXY]-PROPYL}-[2-(BIS-CARBOXYMETHYL-AMINO)-ETHYL]-AMINO}-ACETIC ACID

Toxicity

Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73m2).

The Uses of {{(R)-2-(BIS-CARBOXYMETHYL-AMINO)-3-[(4,4-DIPHENYL-CYCLOHEXYLOXY)-HYDROXY-PHOSPHORYLOXY]-PROPYL}-[2-(BIS-CARBOXYMETHYL-AMINO)-ETHYL]-AMINO}-ACETIC ACID

Diagnostic contrast agent for vascular enhancement of MRI scans.

Indications

Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.

Background

Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.

Pharmacokinetics

Gadofosveset causes signal enhancement by shortening the T1 of water molecules that interact with it. The contrast agent complex's rotation rate is the primary factor determining the magnitude of relaxation enhancement. This relaxation enhancement increase only occurs when bound to human serum albumin.

Metabolism

Gadofosveset does not undergo measurable metabolism.